Search results
Results from the WOW.Com Content Network
QRISK3 (the most recent version of QRISK) is a prediction algorithm for cardiovascular disease (CVD) that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial ...
The results: 82% of patients had low risk (10% or less CHD risk at 10 years). 16% had intermediate risk (10-20%). 3% had high risk (20% or more). [23] High risk was most commonly found in patients with advanced age and was more common in men than women. [medical citation needed]
[33] [34] [35] Rosuvastatin 5 mg and 10 mg are examples of regimens meeting the USPSTF guideline; [32] however, insurers have discretion as to which low- and moderate-dose statin regimens to cover under this requirement, [36] and some only cover other statins. [37] The drug was billed as a "super-statin" during its clinical development; the ...
They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5–10% or greater. [22] In people over the age of 70, statins decrease the risk of cardiovascular disease but only in those with a history of heavy cholesterol blockage in their arteries.
Elevations threefold greater than normal were recorded in 0.5% of people treated with atorvastatin 10 mg-80 mg rather than placebo. [70] Usage instructions in package inserts for this statin define the requirement that hepatic function be assessed with laboratory tests before beginning atorvastatin treatment and repeated periodically as ...
Lovastatin and other statins have been studied for their chemopreventive and chemotherapeutic effects. No such effects were seen in the early studies. [16] More recent investigations revealed some chemopreventive and therapeutic effects, for certain types of cancer, especially in combination of statins with other anticancer drugs. [17]
As the event rate is higher in men than in women, the decrease in events is more easily seen in men than women. [163] In those at risk, but without a history of cardiovascular disease (primary prevention), statins decrease the risk of death and combined fatal and non-fatal cardiovascular disease. [164] The benefit, however, is small. [165]
Acipimox (trade name Olbetam in Europe) is a niacin derivative used as a lipid-lowering agent.It reduces triglyceride levels and increases HDL cholesterol. It may have less marked adverse effects than niacin, although it is unclear whether the recommended dose is as effective as standard doses of niacin.